Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue
References (42)
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women
Lancet
(1992)Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women
Lancet
(1992)- et al.
Tamoxifen-induced tumor stimulation and withdrawal response
Cancer Treat. Rep.
(1979) - et al.
Clinical significance of tamoxifen withdrawal response
Lancet
(1987) - et al.
Tamoxifen withdrawal response: Report of a case
Arch. Intern. Med.
(1989) - et al.
Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
Ann. Oncol.
(1992) - et al.
Contrasting endocrine activity of cis and trans isomers in a series of substituted triphenylethylenes
Nature
(1966) Structure-activity relationships of antioestrogens with regard to interaction with 17 β-estradiol in the mouse uterus and vagina
Acta Endocrinol.
(1971)- et al.
Tamoxifen is a potent “pure” antioestrogen in the chick oviduct
Nature
(1977) - et al.
Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice
Breast Cancer Res. Treat.
(1994) - et al.
The estrogen receptor from a tamoxifen-stimulated MCF-7 tumor variant contains a point mutation in the ligand-binding domain
Breast Cancer Res. Treat.
(1994)
Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with non-isomerizable analogues of tamoxifen and metabolites
J. Natl. Cancer. Inst.
(1993)
The oestrogen receptor: from perception to mechanism
What differentiates antiestrogen-liganded vs. estradiol-liganded estrogen receptor action?
Oncol. Res.
(1992)
Opposing biological actions of antiestrogens in vitro and in vivo: induction of progesterone receptor in the rat and mouse uterus
Endocrinology
(1985)
Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene
EMBO J.
(1991)
Cloning of the rat progesterone receptor gene 5′-region and identification of two functionally distinct promotors
Mol. Endocrinol.
(1993)
A human cell line from a pleural effusion derived from a breast carcinoma
J. Natl. Cancer Inst.
(1973)
Firefly luciferase gene: structure and expression in mammalian cells
Mol. Cell. Biol.
(1987)
Luciferase reporter gene vectors for analysis of promoters and enhancers
BioTechniques
(1988)
An estrogen-responsive element derived from the 5′flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells
Cell
(1986)
Cited by (68)
Human glutathione S-transferase P1-1 functions as an estrogen receptor α signaling modulator
2014, Biochemical and Biophysical Research CommunicationsCitation Excerpt :The expression vector coding for GSTP (GenBank Accession No. NM_000852.3) was generated by inserting the 0.6 kbp long full-length GSTP into the EcoRI/BamHI sites of pIRESneo vector (Clontech, Mountain View, CA) to produce the pIRESneo/GSTP plasmid. The ERE-luciferase plasmid contains three copies of the Xenopus laevis vitellogenin A2 ERE upstream of the fire fly luciferase [13] and is a gift from Dr. V.C. Jordan (Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC). The pSG5 plasmid containing the wild-type human ERα was originally engineered by Professor P. Chambon (Institut National de la Sante et de la Recherche Medicale, Strasbourg, France).
Apigenin suppresses cancer cell growth through ERβ
2006, NeoplasiaTamoxifen Tales: Suggestions for Scientific Survival
2022, Tamoxifen Tales: Suggestions for Scientific SurvivalTurning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team
2021, Breast Cancer Research and TreatmentPrecision therapeutic targeting of human cancer cell motility
2018, Nature Communications
Copyright © 1995 Published by Elsevier Ireland Ltd.